Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.

Annals of diagnostic pathology - 1 Apr 2016

Kurtis Boaz, Zhuge Jian, Ojaimi Caroline, Ye Fei, Cai Dongming, Zhang David, Fallon John T, Zhong Minghao

Abstract excerpt

Increased telomerase activity is associated with almost all types of advanced human cancers with unknown molecular mechanism(s). Two recurrent point mutations in the promoter region of telomerase reverse transcriptase (TERT)--the key subunit of telomerase--have recently been identified in melanoma as well as a small sample of bladder cancer cell lines. However, the incidence and clinical-pathological significance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Transitional Cell

Share to Promoter Regions, Genetic

Share to Telomerase

Share to Urinary Bladder Neoplasms

Share to Urologic Neoplasms

Share to Urothelium

Source

Identifiers

PMID: 27040924
DOI: 10.1016/j.anndiagpath.2015.12.002

Genes

TERT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.PMID 27040924Read ↗

Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management.Semantic proximity Read ↗

Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.Semantic proximity Read ↗

TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.Semantic proximity Read ↗

TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer.Semantic proximity Read ↗

High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder.Semantic proximity Read ↗

Emerging targets in upper tract urothelial carcinomas: the TERT gene.Semantic proximity Read ↗

High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins.Semantic proximity Read ↗

Highly prevalent<i>TERT</i>promoter mutations in bladder cancer and glioblastomaSemantic proximity Read ↗

Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers.Semantic proximity Read ↗

Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.Semantic proximity Read ↗

A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.Semantic proximity Read ↗

TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.